Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
AssigneeSeattle Children's Hospital
InventorsMichael C. Jensen, James Matthaei
Life of this patent
Estimating the term…
Abstract
Aspects of the invention described herein relate to synthetic compounds that are useful for targeting and labeling tumor cells so as to facilitate recognition by binding agents including Chimeric Antigen Receptor T cells (CAR T cells), which are administered to a subject by intravenous or locoregional administration. Several compositions and methods of making and using these compositions to treat or inhibit a disease in a subject are contemplated.
Claims20
A method of forming a complex between an effector cell and a target cell, the method comprising:
- (a) contacting the target cell with a compound comprising a phospholipid, wherein the phospholipid comprises a hydrophobic group, a polar head group, and a target moiety, thereby obtaining a target cell comprising the target moiety;
- and
- (b) contacting the target cell comprising the target moiety with the effector cell, wherein the effector cell comprises a chimeric antigen receptor (CAR), wherein the CAR specifically binds to the target moiety.
A method of forming a complex between an effector cell and a target cell, the method comprising:
- (a) contacting the target cell with a compound comprising a phospholipid, wherein the phospholipid comprises a target moiety, thereby obtaining a target cell comprising the target moiety, wherein the target cell is a non-solid tumor cell, and wherein the compound has the following structure:
- wherein:
- R is the target moiety,
- n is 0 to 21, and
- x is 8 to 22;
- and
- (b) contacting the target cell comprising the target moiety with the effector cell, wherein the effector cell comprises a T cell, wherein the effector cell comprises a chimeric antigen receptor (CAR), and wherein the CAR specifically binds to the target moiety.
Dependencies are inferred from the claim text.